WHO ICTRP trial
Lowering of very long chain fatty acids in patients with X-linked…
NL-OMON22008 · Overview of Medical Research in the Netherlands (NL-OMON) · Recruiting
Key facts
| Trial ID | NL-OMON22008 |
|---|---|
| Public title | Lowering of very long chain fatty acids in patients with X-linked adrenoleukodystrophy (X-ALD): A biochemical study. |
| Scientific title | Lowering of very long chain fatty acids in patients with X-linked adrenoleukodystrophy (X-ALD): A biochemical study. |
| Primary sponsor | Trial medication was provided by Merck, Sharp and Dome (MSD) |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Interventions | 1. All patients participating in the trial will comply to a diet (American Heart Association level 1). 2. All patients will receive 6 months of placebo and 6 months of lovastatin 40 mg daily in random order (double blind, crossover design). |
| Registration date | Apr 6, 2006 |
| Target size | 20 |
| Secondary IDs | NL623;NTR682; : MEC05/175;ISRCTN31565393 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: